You are entering HCP content only

Please note you are entering now content intended only for Healthcare Professionals.

Are you a HCP?

Yes I am a HCP No I am not a HCP
placeUnited Kingdom
Contact & Support
Medtronic / Covidien Products / Hemostasis / Veriset™ hemostatic patch - have confidence that bleeding will stop

The confidence to know bleeding will stop

Watch the video

Giving you and your patients secure peace of mind.

With Veriset™ hemostatic patch, have confidence that bleeding will stop

After more than 6 years of dedicated scientific research and development, Medtronic launched the Veriset™ patch. It is designed to help you achieve hemostasis quickly and consistently, in ~1 minute.1,2,3,†

Unique mode of action

The Veriset™ hemostatic patch is placed over the injury, gentle pressure is applied for 30 seconds.1,2,4

Bleeding has stopped at approximately 1 min.1,2,3,†

How it works

Fast & Reliable

The Veriset™ hemostatic patch works in two ways:

  • Denaturation of red blood cells, resulting in a lower pH and platelets, which are essential for hemostasis, becoming 'trapped' in the oxidised regenerated cellulose, both these events result in the expedition of the bodies own natural coagulation cascade.5
  • And secondly once the patch is activated, via the combination of Trilysine and Polyethylene Glycol, a PEG Hydrogel is formed. This Hydrogel has two effects: firstly to adhere the patch to the tissue and secondly creates a barrier which acts to seal the injured tissue.1,6

Both parts together help to ensure high efficacy hemostasis can be achieved. 

Easy to use

  • Ready to use in both open and laparoscopic procedures with no preparation time4,7
  • Store Veriset™ Hemostatic Patch at room temperature <25°C8,9
  • Designed to easily pass through a trocar7
  • Not contraindicated in a contaminated or infected environment9

User guide
Fast and reliable
 

  • 78% of liver surgery patients achieve hemostasis in ≤1 minute1,10,†
  • Hold for only 30 seconds1,2,4
  • Single application sufficient to stop most bleeds1,2
Increased Patient Safety

  • Maintains efficacy post-surgery - no re-operative device related bleeding reported after 5 days1,2
  • Patch is fully absorbed in approximately 28 days10
  • Offers bactericidal properties9
Effective
 

  • Effective in cases of inhibited coagualation, independent of clotting ability11,12
  • Achieve hemostasis quickly and consistently - 66% faster than TachoSil™* fibrin patch1,10

Clinical evidence

Achieved hemostasis significantly faster than the control device1,10

The Veriset™ hemostatic patch is effective in promoting hemostatis and does not elicit any safety concerns.2

Regardless of bleeding severity or surface area, the Veriset™ hemostatic patch achieved hemostasis significantly faster than the control device in patients undergoing hepatic resection. It was safe and easy to handle in open and laparoscopic hepatic surgery.1,7,10

Interested in learning more about the Veriset™ Hemostatic Patch?

Contact us today
References

† Based on surgeon/customer validation. In several clinical investigations, the median times to hemostasis were within 1 minute. In one clinical investigation, the median time to hemostasis was within 1.5 minutes when used in cardiovascular application.

1. Öllinger R, Mihaljevic AL, Schuhmacher C, et al. A multicentre, randomized clinical trial comparing the Veriset™ hemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery. HPB (Oxford). 2013;15(7):548-58. doi: 10.1111/hpb.12009.

2. Schuhmacher C, Pratschke J, Weiss S, et al. Safety and effectiveness of a synthetic hemostatic patch for intraoperative soft tissue bleeding. Med Devices. 2015;8:167–174.

3. Glineur D, Hendrikx M, Krievins D, et al. A randomized, controlled trial of Veriset™ hemostatic patch in halting cardiovascular bleeding. Med Devices: Evidence and Research. 2018;11:65-75

4. Based on internal test report # TR1431, Hemostasis Patch: Evaluation of Product Performance Against Product Specification in an Acute Pre-Clinical Model. June 2010.

5. Bajerova Martina, Krejcova Katerina, Rabiskova Miloslava, et al. Oxycellulose: Significant Characteristics in Relation to Its Pharmaceutical and Medical Application. Advances in Polymer Technology. Vol. 28, No. 3, pp. 199–208. Science Direct. Oxidized Cellulose. https://www.sciencedirect.com/topics/neuroscience/oxidized-cellulose. Accessed Feb. 25, 2020.

6. Based on internal test report TR1444, Long-term Evaluation of a Polyethylene Glycol(PEG)/Oxidized Cellulose Hemostatic Patch after Liver Resection in a Porcine Model. June 2011.

7. Based on internal test report #TR1478, Evaluation of Veriset™ after Laparoscopic Liver Resection in Porcine Model. June 2013

8. Based on internal testing report #TR1477, Veriset Stability at Maximum Irradiation Dose - 104 week Final Report. March 2015

9. Veriset Hemostatic Patch [instruction for use], North Haven, CT - USA : Medtronic 2018

10. Based on internal report #COVEULV0032, A Prospective, Multi-Center, Randomized, Single-Blind Study to Compare the Hemostatic Patch to Fibrin Sealant TachoSil™* in Subjects undergoing Hepatic Surgery, appendix B. January 2012.

11. Based on internal test report #COVEUCV0140-CSR - A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil™* as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery. March 2014.

12. Based on internal testing report #TR1428, Evaluation of a Polyethylene Glycol (PEG)/Oxidized Cellulose Hemostatic Patch on the Anastomotic site in a Porcine CABG Model. March 2011